amplifyeyecare-logo-base2-icon
Authors
Pediatric Eye Disease Investigator Group; Michael X Repka, Raymond T Kraker, Roy W Beck, Jonathan M Holmes, Susan A Cotter, Eileen E Birch, William F Astle, Danielle L Chandler, Joost Felius, Robert W Arnold, D Robbins Tien, Stephen R Glaser

A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years

publication date
Category
see more

Abstract/Introduction

Objective: To determine the visual acuity outcome at age 10 years for children younger than 7 years when enrolled in a treatment trial for moderate amblyopia.

 

Methods: In a multicenter clinical trial, 419 children with amblyopia (visual acuity, 20/40-20/100) were randomized to patching or atropine eyedrops for 6 months. Two years after enrollment, a subgroup of 188 children entered long-term follow-up. Treatment after 6 months was at the discretion of the investigator; 89% of children were treated.

 

Main outcome measure: Visual acuity at age 10 years with the electronic Early Treatment Diabetic Retinopathy Study test.

Application to clinical practice: Patching and atropine eyedrops produce comparable improvement in visual acuity that is maintained through age 10 years.


Conclusion/Results

Results: The mean amblyopic eye acuity, measured in 169 patients, at age 10 years was 0.17 logMAR (logarithm of the minimum angle of resolution) (approximately 20/32), and 46% of amblyopic eyes had an acuity of 20/25 or better. Age younger than 5 years at entry into the randomized trial was associated with a better visual acuity outcome (P < .001). Mean amblyopic and sound eye visual acuities at age 10 years were similar in the original treatment groups (P = .56 and P = .80, respectively).

Conclusions: At age 10 years, the improvement of the amblyopic eye is maintained, although residual amblyopia is common after treatment initiated at age 3 years to younger than 7 years. The outcome is similar regardless of initial treatment with atropine or patching.


Contact Us To Amplify Your EyeCare

Learn More 

arrow-uparrow-right